Depression FDA - Search News

FDA Approves ‘Spravato’ Nasal Spray

FDA approves first-of-its-kind nasal spray for severe depression

Johnson & Johnson has announced the FDA’s approval of a first-of-its-kind, esketamine nasal spray called Spravato for the standalone treatment of major depressive disorder (MDD), PTSD, and similar psychiatric conditions.

Hosted on MSN · 2d

FDA Approves Nasal Spray for Depression

The nasal spray Spravato, which is made from the drug esketamine, had been approved in 2019 for patients who failed to respond to at least two oral antidepressants.

UPI News on MSN · 2d

FDA approves Spravato, first monotherapy nasal spray to treat depression

The Food and Drug Administration has approved the first-ever stand-alone nasal spray to treat drug-resistant depression. Johnson & Johnson's Spravato was approved to treat a major depressive disorder,

mic3d

A Nasal Spray For Depression? FDA Gives Its Approval

The U.S. Food and Drug Administration (FDA ... This innovative treatment is poised to change the landscape of depression management, particularly for those grappling with treatment-resistant ...

The Hill2d

Nose spray to treat depression? FDA approves first-of-its-kind medicine

NEW YORK (WPIX) – The U.S. Food and Drug Administration has approved a nose spray to help treat depression, Johnson & Johnson announced Tuesday. Spravato is a first-of-its-kind medication to ...

ScienceAlert on MSN1d

FDA-Approved Nasal Spray For Depression Is First Of Its Kind

A ketamine-based nasal spray is officially the first and only standalone therapy available for treatment-resistant depression ...

Some results have been hidden because they may be inaccessible to you

Show inaccessible results

FDA Approves ‘Spravato’ Nasal Spray

Trending now